Nipah Outbreak Prevention and Control Challenges? ERA Technology Empowers Precise Dual-Virus Prevention and Control-GenDx Biotech

On January 26, 2026, Xinhua News Agency cited foreign media reports indicating a sudden cluster outbreak of Nipah virus (NiV) in West Bengal, India. Five confirmed cases have been reported, including one in critical condition, with nearly 100 individuals placed under home quarantine. Neighboring countries have swiftly enhanced quarantine and monitoring measures, initiating cross-border prevention and control efforts.

▲ Indian medical workers handling contaminated items

1. Nipah Virus: The Dual Threats of High Lethality and Stealth Transmission

Nipah virus belongs to the *Henipavirus* genus within the *Paramyxoviridae* family. Since its initial outbreak in 1998, it has remained a critical focus for global public health prevention and control.
The difficulty in controlling the virus stems from three core characteristics:

First, it has an extremely high fatality rate, ranging from 40% to 75%, and even exceeding 90% in certain outbreaks—far surpassing that of common respiratory infectious diseases.

Second, it possesses diverse transmission routes. Fruit bats are its natural reservoir hosts, and it can spread through animal-to-human, human-to-human, and environmental pathways. Human-to-human transmission is particularly stealthy, posing a significant risk of nosocomial infection.

Third, there are currently no approved specific drugs or vaccines for NiV. Clinical management is limited to symptomatic and supportive care.

Nipah virus outbreaks are concentrated in South and Southeast Asia and are prone to cluster occurrences during the winter date palm sap season. The current outbreak in West Bengal underscores the recurrent nature of this virus.

2. A Diagnostic Conundrum: The Dual Impact of Misdiagnosis on Prevention and Control

Influenza A and B are seasonal infectious diseases whose global prevalence is currently in a phase of "peak decline with stabilized strains." The initial symptoms of Nipah virus infection are highly similar to those of influenza A and B, making accurate differentiation based solely on incubation period and symptom progression difficult. Misdiagnosis can not only delay early intervention for Nipah virus but may also exacerbate influenza spread and lead to misallocation of medical resources. This highlights the urgent need for rapid detection tools capable of simultaneously identifying both types of pathogens.

尼帕病毒与流感检测：先达基因快速检测(1).png

▲ Nipah virus outbreak in India (Source: Video screenshot)

3. Accurate Detection: The Core Strategy for Addressing the Dual Epidemic Challenge

GenDx Biotech's GCP-30 Ultra-Multiplex Assay is precisely designed to resolve this clinical differential diagnosis dilemma. Utilizing the core technology of Enzymatic Recombinase Amplification (ERA), this assay can rapidly and simultaneously detect Nipah virus, Influenza A, and Influenza B within 20 minutes. Furthermore, it is capable of screening for up to 30 pathogens in a single test, significantly improving detection efficiency in complex scenarios. It accurately avoids cross-reactivity with other respiratory pathogens, reducing the risk of misdiagnosis at the source.

图三(1).png

Among current influenza detection technologies, virus isolation and culture are primarily suited for research, while antigen tests often have lower sensitivity and a higher risk of false-negative results. In contrast, the ERA technology employed by the GCP-30 does not require large-scale PCR instruments and can perform detection at a constant temperature. Compared to traditional nucleic acid testing, it is more suitable for complex prevention and control scenarios such as primary healthcare institutions and field testing, making it an optimal solution for rapid screening during sudden outbreaks.

The GCP-30 meets the core needs of rapidity, accuracy, multi-target capability, and scenario adaptability for dual epidemic prevention and control. It not only addresses the differential diagnosis challenge posed by overlapping symptoms but also overcomes the scenario limitations of traditional testing with its portable advantages. Currently, the GCP-30 has obtained CE certification overseas. GenDx Biotech provides comprehensive technical training and 24-hour technical consulting services, supported by a global supply chain. This enables a rapid response to the prevention and control needs of affected regions worldwide, ensures stable product performance in practical applications, and provides a powerful tool for global public health efforts.

4. Conclusion
The current outbreak serves as a reminder of the need to adhere to tiered and classified prevention and control strategies, implement the "One Health" concept, and strengthen technological empowerment and global collaboration. The future of public health prevention and control lies in precision and intelligent advancement. GenDx Biotech will continue to deepen research and development in isothermal amplification technology, develop multi-pathogen combination detection products, and contribute to building a robust prevention and control system.

In the face of epidemic threats, accurate detection forms the core line of defense. With its rapid, accurate, and convenient detection solutions, GenDx Biotech provides strong support for global epidemic prevention and control, safeguarding the barriers protecting human health.

News & Events

+86-133 5801 3751

Nipah Outbreak Prevention and Control Challenges? ERA Technology Empowers Precise Dual-Virus Prevention and Control

Previous

Next